---
title: "600557.SH (600557.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600557.SH/news.md"
symbol: "600557.SH"
name: "600557.SH"
parent: "https://longbridge.com/en/quote/600557.SH.md"
datetime: "2026-05-21T07:28:16.508Z"
locales:
  - [en](https://longbridge.com/en/quote/600557.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600557.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600557.SH/news.md)
---

# 600557.SH (600557.SH) — Related News

### [](https://longbridge.com/en/news/286527433.md)
*2026-05-15T07:54:16.000Z*
> The National Healthcare Security Administration issued implementation opinions on reforming and improving the supply gua

### [Exchanging short-term profits for long-term pipelines, how should the accounts of traditional Chinese medicine innovation be calculated?](https://longbridge.com/en/news/284387483.md)
*2026-04-28T12:18:25.000Z*
> Kanion Pharmaceutical released its 2025 annual report, with total operating revenue of 3.293 billion yuan, a year-on-yea

### [Kanion Pharmaceutical: Net profit of 304 million yuan in 2025, a year-on-year decrease of 22.44%](https://longbridge.com/en/news/283653675.md)
*2026-04-22T11:23:27.000Z*
> Kanion Pharmaceutical announced that the operating revenue in 2025 will be 3.293 billion yuan, a year-on-year decrease o

### [Healthcare Industry Daily (04.19): Frontline Dynamics in Pharmaceuticals](https://longbridge.com/en/news/283262830.md)
*2026-04-19T19:11:18.000Z*
> KHPG's subsidiary KHN921 injection has received FDA clinical trial approval for the indication of hypertrophic cardiomyo

### [Kanion Pharmaceutical received the clinical trial approval notice for Qingshen Tongluo Granules](https://longbridge.com/en/news/283245223.md)
*2026-04-19T07:42:05.000Z*
> Kanion Pharmaceutical recently received the "Drug Clinical Trial Approval Notice" for Qingshen Tongluo Granules issued b

### [Kanion Pharmaceutical's core improved variety approval encounters obstacles, and the launch of ReDuNing granules is postponed](https://longbridge.com/en/news/278859778.md)
*2026-03-12T09:52:19.000Z*
> Kanion Pharmaceutical's Re Du Ning granules were not approved in the review by the National Medical Products Administrat

### [Kanion Pharmaceutical: Clinical trial for Black, Yellow, and Red Pearl Granules approved](https://longbridge.com/en/news/276869242.md)
*2026-02-25T10:14:07.000Z*
> Kanion Pharmaceutical announced that it recently received the "Drug Clinical Trial Approval Notification" issued by the 

### [Kanion Pharmaceutical: Appointed Zhang Xiaoliang as Deputy General Manager](https://longbridge.com/en/news/276697977.md)
*2026-02-24T07:35:50.000Z*
> On February 24th, Kanion Pharmaceutical announced that, upon the nomination of the company's general manager, the specia

### [Eight departments issued a heavy document! The Chinese medicine sector exploded, Zhendong Pharmacy surged over 19%, TY PHAR. and Hansen Pharmaceutical hit the daily limit](https://longbridge.com/en/news/275061561.md)
*2026-02-06T02:27:17.000Z*
> The Chinese medicine sector surged against the trend in the morning session, with Zhendong Pharmacy rising over 19%, and

### [Kanion Pharmaceutical: Received the clinical trial approval notice for the Yunpi Huatan Tongqiao granule medication](https://longbridge.com/en/news/273701090.md)
*2026-01-26T12:32:37.000Z*
> On January 26th, Kanion Pharmaceutical announced that the company recently received the "Drug Clinical Trial Approval No